| 000 | 01803 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250516130101.0 | ||
| 264 | 0 | _c20130830 | |
| 008 | 201308s 0 0 eng d | ||
| 022 | _a1468-1331 | ||
| 024 | 7 |
_a10.1111/ene.12057 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZach, H | |
| 245 | 0 | 0 |
_aThe effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis. _h[electronic resource] |
| 260 |
_bEuropean journal of neurology _cApr 2013 |
||
| 300 |
_a708-13 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAge of Onset |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAutoantibodies _xblood |
| 650 | 0 | 4 |
_aBlepharoptosis _xetiology |
| 650 | 0 | 4 |
_aCholinesterase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 |
_aEye Diseases _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMuscle Weakness _xetiology |
| 650 | 0 | 4 |
_aMyasthenia Gravis _xdrug therapy |
| 650 | 0 | 4 |
_aOculomotor Muscles _xphysiopathology |
| 650 | 0 | 4 |
_aPrednisolone _xtherapeutic use |
| 650 | 0 | 4 |
_aPyridostigmine Bromide _xtherapeutic use |
| 650 | 0 | 4 |
_aReceptors, Cholinergic _ximmunology |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Assessment |
| 700 | 1 | _aCetin, H | |
| 700 | 1 | _aHilger, E | |
| 700 | 1 | _aPaul, A | |
| 700 | 1 | _aWuschitz, B | |
| 700 | 1 | _aJung, R | |
| 700 | 1 | _aAuff, E | |
| 700 | 1 | _aZimprich, F | |
| 773 | 0 |
_tEuropean journal of neurology _gvol. 20 _gno. 4 _gp. 708-13 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/ene.12057 _zAvailable from publisher's website |
| 999 |
_c22384066 _d22384066 |
||